Financial Summary for the Second Quarter (Interim) of the Fiscal Year Ending February 2027 [Japanese GAAP] (Consolidated)

Overview of Results

For the interim period, consolidated net sales amounted to 28,255 million yen (up 4.9% YoY). Operating income, including selling, general and administrative expenses, was 821 million yen (up 10.4% YoY), ordinary income was 1,135 million yen (up 29.0% YoY), and net income attributable to owners of the parent was 850 million yen (up 27.5% YoY), showing favorable results. By segment, dispensing pharmacy recorded net sales of 13,215 million yen (+1.2%) and profit of 610 million yen; healthcare recorded net sales of 4,685 million yen (+6.9%) and profit of 44 million yen; pharmaceutical wholesaling recorded net sales of 10,219 million yen (+9.0%) and profit of 148 million yen. Newly acquired businesses contributed, and real estate and investments also provided support.

Outlook and Capital Allocation

Cash and cash equivalents at the end of the interim period were 7,121 million yen. Operating cash flow increased by 2,440 million yen, investing cash flow increased by 67 million yen, and financing cash flow decreased by 1,136 million yen. The full-year performance forecast remains unchanged from the previously announced outlook, and the company discloses that revisions may be made depending on future performance, including the impact of M&A.